Close Menu

NEW YORK (GenomeWeb) – Lucence Diagnostics said today that it has partnered with Myanmar-based firm Mascots Medical and Laboratory Centre to distribute Lucence's blood-based cancer diagnostic tests and treatment in Myanmar.

Under the terms of the agreement, Mascots will distribute Lucence's blood tests, which detect DNA fragments shed by a tumor into the blood to identify cancer-driving mutations. The assays target a variety of cancers, including breast, colon, lung, and pancreatic cancers.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.